Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats

Neurochemical Research

Volumn 38, Issue 8, 2013, Pages 1572-1579

  Ola, M Shamsul ^a   Ahmed, Mohammed M ^b   Abuohashish, Hatem M ^b   Al Rejaie, Salim S ^b   Alhomida, Abdullah S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Apoptosis; Brain derived neurotrophic factor; Diabetic retinopathy; Neurodegeneration; Retina; Telmisartan

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CILIARY NEUROTROPHIC FACTOR; GLUTATHIONE; TELMISARTAN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RETINA; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DIABETES MELLITUS, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN;

RATTUS;

EID: 84879692686     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1058-4     Document Type: Article

References (44)

1. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM (2004) Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 122:1631-1640
2. Clermont A, Bursell SE, Feener EP (2006) Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J Hypertens Suppl 24:S73-S80
3. Sjølie AK (2007) Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res Clin Pract 1:S31-S39
4. Gurley SB, Coffman TM (2007) The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 27:144-152
5. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y, Ishida S (2009) (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 58:1625-1633
6. Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K, Ishida S (2007) Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 48:4342-4350
7. Danser AH, van-den-Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de-Jong PT, Schalekamp MA (1989) Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 68:160-167
8. Funatsu H, Yamashita H, Nakanishi Y, Hori S (2002) Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 86:311-315
9. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK (2008) DIRECT programme study group: effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372:1394-1402
10. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40-51
11. Ola MS, Nawaz MI, Siddiquei MM, Al-Amro S, Abu El-Asrar AM (2012) Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. J Diabetes Complications 26:56-64
12. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783-791
13. Mohr S, Xi X, Tang J, Kern TS (2002) Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 51:1172-1179
14. Kurihara T, Ozawa Y, Nagai N, Shinoda K, Noda K, Imamura Y, Tsubota K, Okano H, Oike Y, Ishida S (2008) Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 57:2191-2198
15. Yang H, Hirooka K, Fukuda K, Shiraga F (2009) Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest Ophthalmol Vis Sci 50:5800-5804
16. Kurihara T, Ozawa Y, Shinoda K, Nagai N, Inoue M, Oike Y, Tsubota K, Ishida S, Okano H (2006) Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci 47:5545-5552
17. Pd S, Drazba J, Shadrach K, Milsted A, Rungger-Brandle E, Nishiyama K, Miura S, Karnik S, Sears JE, Hollyfield JG (2007) Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci 48:3301-3311
18. Downie LE, Vessey K, Miller A, Ward MM, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL (2009) Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience 161:195-213
19. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148
20. Chen P, Guo AM, Edwards PA, Trick G, Scicli AG (2007) Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. Am J Physiol Regul Integr Comp Physiol 293:R1619-R1629
21. Silva KC, Rosales MA, Biswas SK, Lopes-de-Faria JB, Lopes-de-Faria JM (2009) Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes 58:1382-1390
22. Ozawa Y, Kurihara T, Sasaki M, Ban N, Yuki K, Kubota S, Tsubota K (2011) Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model. Exp Diabetes Res 2011:108328
23. Fujita T, Hirooka K, Nakamura T, Itano T, Nishiyama A, Nagai Y, Shiraga F (2012) Neuroprotective effects of angiotensin II type 1 receptor (AT1-R) blocker via modulating AT1-R signaling and decreased extracellular glutamate levels. Invest Ophthalmol Vis Sci 53:4099-4110
24. Kakuta H, Sudoh K, Sasamata M, Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 25(1):41-46
25. Zou Z, Xi GL, Yuan HB, Zhu QF, Shi XY (2009) Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. J Hum Hypertens 23(5):339-349
26. Sleight P (2009) Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. J Hypertens Suppl 27(5):S23-S29
27. Chan SH, Wu CW, Chang AY, Hsu KS, Chan JY (2010) Transcriptional upregulation of brain-derived neurotrophic factor in rostral ventrolateral medulla by angiotensin II: significant in superoxide homeostasis and neural regulation of arterial pressure. Circ Res 107:1127-1139
28. Kishi T, Hirooka Y, Sunagawa K (2012) Sympathoinhibition caused by orally administeredtelmisartan through inhibition of the AT1 receptor in the rostralventrolateral medulla of hypertensive rats. Hypertens Res PMID: 22948091
29. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, Abe H, Takei N (2004) Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induceddiabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53:2412-2419
30. Sasaki M, Ozawa Y, Kurihara T, Kubota S, Yuki K, Noda K, Kobayashi S, Ishida S, Tsubota K (2010) Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 53:971-979
31. Ola MS, Nawaz MI, El-Asrar AA, Abouammoh M, Alhomida AS (2013a) Reduced Levels of Brain Derived Neurotrophic Factor (BDNF) in the Serum of Diabetic Retinopathy Patients and in the Retina of Diabetic Rats. Cell Mol Neurobiol PMID: 23271640
32. Lee TH, Yang JT, Kato H, Wu JH (2006) Hypertension downregulates the expression of brain-derived neurotrophic factor in the ischemic-vulnerable hippocampal CA1 and cortical areas after carotid artery occlusion. Brain Res 1116:31-38
33. Zacchigna S, Lambrechts D, carmeliet P (2008) Neurovascular signalling defects in neurodegeneration. Nat Rev 9:169-181
34. Pease ME, Zack DJ, Berlinicke C, Bloom K, Cone F, Wang Y, Klein RL, Hauswirth WW, Quigley HA (2009) Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci 50:2194-2200
35. Grammatopoulos TN, Jones SM, Ahmadi FA, Hoover BR, Snell LD, Skoch J, Jhaveri VV, Poczobutt AM, Weyhenmeyer JA, Zawada WM (2007) Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener 15(2):1
36. Mertens B, Varcin M, Michotte Y, Sarre S (2011) The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death. Eur J Neurosci 34:1141-1148
37. Ola MS, Nawaz MI, Khan HA, Alhomida AS (2013) Neurodegeneration and neuroprotection in diabetic retinopathy. Int J Mol Sci 14:2559-2572
38. Miao X, Lv H, Wang B, Chen Q, Miao L, Su G, Tan Y (2013) Deletion of angiotensin II Type 1 receptor gene attenuates chronic alcohol-induced retinal ganglion cell death with preservation of VEGF expression. Curr Eye Res 38:185-193
39. Wilkinson-Berka JL (2006) Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 38:752-765
40. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL (2010) The renin-angiotensin system in retinal health and disease: its influence on neurons, glia and the vasculature. Prog Retin Eye Res 29:284-311
41. Miller AG, Tan G, Binger KJ, Pickering RJ, Thomas MC, Nagaraj RH, Cooper ME, Wilkinson-Berka JL (2010) Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 59:3208-3215
42. Kagota S, Tada Y, Nejime N, Nakamura K, Kunitomo M, Shinozuka K (2011) Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome. Can J PhysiolPharmacol 89:355-364
43. Krikov M, Thone-Reineke C, Müller S, Villringer A, Unger T (2008) Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens 26:544-552
44. Gastinger MJ, Singh RS, Barber AJ (2006) Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 47:3143-3150